Using monthly injectable buprenorphine to treat opioid addiction in prisons
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews
This study is testing if a monthly injectable medication for opioid addiction can help people in prison stick to their treatment better than daily options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Lifespan Academic / other |
| Locations | 1 site (Cranston, Rhode Island) |
| Trial ID | NCT06354465 on ClinicalTrials.gov |
What this trial studies
This observational study explores the feasibility and effectiveness of extended-release buprenorphine (XR-B) as a treatment for opioid use disorder (OUD) among incarcerated individuals. Through qualitative interviews with inmates and stakeholders, the research aims to identify the potential benefits and challenges of implementing this monthly injectable medication compared to daily treatments. The study seeks to determine which segments of the prison population may benefit most from XR-B, providing insights into treatment adherence and compliance in a correctional setting.
Who should consider this trial
Good fit: Ideal candidates for this study are English-speaking incarcerated individuals over the age of 18 who have been diagnosed with opioid use disorder.
Not a fit: Patients with severe, persistent mental illness may not benefit from this study due to the complexities of their conditions and the need for specialized treatment.
Why it matters
Potential benefit: If successful, this approach could improve treatment adherence for opioid use disorder in correctional facilities, leading to better health outcomes for incarcerated individuals.
How similar studies have performed: While this approach is innovative in a correctional context, similar studies on extended-release buprenorphine have shown promise in other settings, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Incarcerated individuals, inclusion criteria: * English speaking * Over the age of 18 * Diagnosed with opioid use disorder Incarcerated individuals, Exclusion Criteria: - Diagnosed with "Severe, Persistent, Mental Illness (SPMI)" Rationale for Exclusion: These individuals suffer from severe mental health disease and therefore warrant greater protection, have greater risk for coercion, and offer insights to severe co-diagnosis treatment that, while important, remain outside the scope of general MAT implementation. Organizational Stakeholders, Inclusion Criteria: - Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program Organizational Stakeholders, Exclusion Criteria: - If not permitted by their organizational union to participate
Where this trial is running
Cranston, Rhode Island
- Rhode Island Department of Corrections — Cranston, Rhode Island, United States (Recruiting)
Study contacts
- Principal investigator: Justin Berk, MD — Lifespan
- Study coordinator: Justin Berk, MD
- Email: justin_berk@brown.edu
- Phone: 8064333960
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.